Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study

被引：0

作者：

Blas, Leandro ^{[1
]}

Shiota, Masaki ^{[1
]}

Kato, Takuma ^{[2
]}

Matsumoto, Ryuji ^{[3
]}

Tohi, Yoichiro ^{[2
]}

Sakamoto, Shinichi ^{[4
]}

Yokomizo, Akira ^{[5
]}

Kimura, Takahiro ^{[6
]}

Furukawa, Junya ^{[7
]}

Shoji, Sunao ^{[8
]}

Kume, Haruki ^{[9
]}

Goto, Takayuki ^{[10
]}

Sekine, Yoshitaka ^{[11
]}

Sakai, Yasuyuki ^{[12
]}

Matsuoka, Yoh ^{[13
]}

Hinata, Nobuyuki ^{[14
]}

Kamoto, Toshiyuki ^{[15
]}

Terada, Naoki ^{[16
]}

Akamatsu, Shusuke ^{[17
]}

Sugimoto, Mikio ^{[2
]}

Eto, Masatoshi ^{[1
]}

机构：

[1] Kyushu Univ, Grad Sch Med Sci, Dept Urol, Fukuoka, Japan

[2] Kagawa Univ, Fac Med, Dept Urol, Takamatsu, Kagawa, Japan

[3] Hokkaido Univ, Dept Urol, Grad Sch Med, Sapporo, Japan

[4] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan

[5] Harasanshin Hosp, Dept Urol, Fukuoka, Japan

[6] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan

[7] Tokushima Univ, Grad Sch Biomed Sci, Dept Urol, Tokushima, Japan

[8] Tokai Univ, Sch Med, Dept Urol, Isehara, Kanagawa, Japan

[9] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto, Japan

[11] Gunma Univ, Grad Sch Med, Dept Urol, Maebashi, Gunma, Japan

[12] Tsuchiura Kyodo Gen Hosp, Dept Urol, Tsuchiura, Ibaraki, Japan

[13] Saitama Canc Ctr, Dept Urol, Saitama, Japan

[14] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Urol, Hiroshima, Japan

[15] Miyazaki Univ, Fac Med, Dept Urol, Miyazaki, Japan

[16] Univ Fukui, Fac Med Sci, Dept Urol, Fukui, Japan

[17] Nagoya Univ, Grad Sch Med, Dept Urol, Nagoya, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2025年

关键词：

active surveillance; PRIAS; prostate cancer; prostate-specific antigen; RADICAL PROSTATECTOMY; TERM OUTCOMES; FOLLOW-UP; MEN;

D O I：

10.1111/iju.70063

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

ObjectivesTo report outcomes of active surveillance (AS) for prostate cancer in men with intermediate-risk features of International Society of Urological Pathology (ISUP) grade group 2 and/or clinical stage T2 compared with ISUP grade group 1 and clinical stage T1 in the PRIAS-JAPAN study.MethodsPatients with prostate cancer diagnosed between January 2010 and February 2024 were included in this study. PSA test, rectal examination, and re-biopsy were performed regularly. We calculated the pathological reclassification rate, program persistence rate, and subsequent treatment.ResultsData from 1302 participants were collected. After excluding patients who did not fit inclusion criteria (n = 28) or follow-up of less than 1 year (n = 208), 1066 patients were included in this analysis. The median follow-up was 42.4 months (interquartile range 17.0-72.1). There were no statistical differences in the pathological reclassification, persistence rates, and subsequent therapy between low- and intermediate-risk features.ConclusionThis preliminary study demonstrated medium-term outcomes of AS in prostate cancer with intermediate-risk features in Japan, suggesting no significant difference in the pathological reclassification, persistence rate, and subsequent therapy between low- and intermediate-risk features.

引用

页数：5

共 50 条

[31] Prognostic Value of the Intermediate-risk Feature in Men with Favorable Intermediate-risk Prostate Cancer: Implications for Active Surveillance
Sherer, Michael, V
Leonard, Austin J.
Nelson, Tyler J.
Guram, Kripa
De Moraes, Gustavo Rodrigues
Javier-Desloges, Juan
Kane, Christopher
McKay, Rana R.
Rose, Brent S.
Bagrodia, Aditya
EUROPEAN UROLOGY OPEN SCIENCE, 2023, 50 : 61 - 67
[32] Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study
Bul, Meelan
Zhu, Xiaoye
Valdagni, Riccardo
Pickles, Tom
Kakehi, Yoshiyuki
Rannikko, Antti
Bjartell, Anders
van der Schoot, Deric K.
Cornel, Erik B.
Conti, Giario N.
Boeve, Egbert R.
Staerman, Frederic
Vis-Maters, Jenneke J.
Vergunst, Henk
Jaspars, Joris J.
Stroelin, Petra
van Muilekom, Erik
Schroder, Fritz H.
Bangma, Chris H.
Roobol, Monique J.
EUROPEAN UROLOGY, 2013, 63 (04) : 597 - 603
[33] Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance
Dall'Era, Marc A.
Davies, Benjamin J.
EUROPEAN UROLOGY FOCUS, 2015, 1 (02): : 208 - 209
[34] Prospective validation of active surveillance in prostate cancer: The PRIAS study
van den Bergh, Roderick C. N.
Roemeling, Stijn
Roobol, Monique J.
Roobol, Wouter
Schroder, Fritz H.
Bangma, Chris H.
EUROPEAN UROLOGY, 2007, 52 (06) : 1560 - 1563
[35] The impact of complications after diagnostic biopsy on repeat biopsy in men: Results from the Prostate Cancer Research International: Active surveillance (PRIAS-JAPAN) study.
Tohi, Yoichiro
Kato, Takuma
Matsumoto, Ryuji
Shinohara, Nobuo
Yokomizo, Akira
Mitsuzuka, Koji
Nakamura, Masaki
Kume, Haruki
Sugimoto, Mikio
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[36] Risk Group and Death From Prostate Cancer Implications for Active Surveillance in Men With Favorable Intermediate-Risk Prostate Cancer
Raldow, Ann C.
Zhang, Danjie
Chen, Ming-Hui
Braccioforte, Michelle H.
Moran, Brian J.
D'Amico, Anthony V.
JAMA ONCOLOGY, 2015, 1 (03) : 334 - 340
[37] Active surveillance in favorable intermediate-risk prostate cancer: A single-center experience
Bandelier, Q.
Bastide, C.
Charvet, A. -L
Leclercq, L.
Gondran-Tellier, B.
Campagna, J.
Long-Depaquit, T.
Daniel, L.
Rossi, D.
Lechevallier, E.
Baboudjian, M.
FRENCH JOURNAL OF UROLOGY, 2024, 34 (01):
[38] Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
Courtney, P. Travis
Deka, Rishi
Kotha, Nikhil, V
Cherry, Daniel R.
Salans, Mia A.
Nelson, Tyler J.
Kumar, Abhishek
Luterstein, Elaine
Yip, Anthony T.
Nalawade, Vinit
Parsons, J. Kellogg
Kader, A. Karim
Stewart, Tyler F.
Rose, Brent S.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (02): : 151 - +
[39] Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer
Butler, Santino S.
Mahal, Brandon A.
Lamba, Nayan
Mossanen, Matthew
Martin, Neil E.
Mouw, Kent W.
Nguyen, Paul L.
Muralidhar, Vinayak
CANCER, 2019, 125 (18) : 3164 - 3171
[40] Active Surveillance or Watchful Waiting for Intermediate-Risk Prostate Cancer, 2010-2020
Ajjawi, Ismail
Loeb, Stacy
Cooperberg, Matthew R.
Catalona, William J.
Gross, Cary P.
Ma, Xiaomei
Leapman, Michael S.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 332 (23): : 2033 - 2036

← 1 2 3 4 5 →